Abatacept therapy and safety management
References (61)
- et al.
Cytokines and T cells in host defense
Curr Opin Immunol
(2000) - et al.
Role of T cell costimulation in antiviral immunity
Semin Immunol
(2004) - et al.
The host response of CD28-deficient mice to pneumocystis infection
Microb Pathog
(2006) - et al.
Mortality in established rheumatoid arthritis
Best Pract Res Clin Rheumatol
(2007) - et al.
Infection and musculoskeletal conditions: bacterial and opportunistic infections during anti-TNF therapy
Best Pract Res Clin Rheumatol
(2006) - et al.
Comorbidities in rheumatoid arthritis
Best Pract Res Clin Rheumatol
(2007) - et al.
Human CTLA-4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies
Blood
(2005) - et al.
Transmission disequilibrium of maternally-inherited CTLA-4 microsatellite alleles in idiopathic recurrent miscarriage
J Reprod Immunol
(1998) Fetal tolerance in human pregnancy – A crucial balance between acceptance and limitation of trophoblast invasion
Immunol Lett
(2008)- et al.
Blockade of CD80 and CD86 at the time of implantation inhibits maternal rejection to the allogeneic fetus in abortion-prone matings
J Reprod Immunol
(2005)
Étude de la réponse immunitaire au vaccin antigrippal chez les patients ayant une polyarthrite rhumatoïde et traités par abatacept
Rev Rheum
Antibiotic prophylaxis in dentistry: a review and practice recommendations
J Am Dent Assoc
Anti-TNF alpha therapy and safety monitoring. Clinical tool guide elaborated by the Club Rhumatismes et Inflammation (CRI), section of the French Society of Rheumatology (Société Française de Rhumatologie, SFR)
Joint Bone Spine
Rituximab (Mabthera) therapy and safety management. Clinical tool guide elaborated by the Rheumatic Diseases and inflammation Group (Club Rhumatismes et Inflammation, CRI), of the French Society of Rheumatology (Société Française de Rhumatologie, SFR)
Joint Bone Spine
Time to treatment response with abatacept in patients with rheumatoid arhritis and an inadequate response to methotrexate
Arthritis Rheum
Time to treatment response with abatacept in patients with RA and an inadequate response to anti-TNF therapy
Arthritis Rheum
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor inhibition
N Engl J Med
Costimulation in resistance to infection and development of immune pathology: lessons from toxoplasma
Immunol Res
Differential CD28 and inducible costimulatory molecule signalling requirements for protective CD4+ T-cell-mediated immunity against genital tract Chlamydia trachomatis infection
Infect Immun
Abatacept treatment does not exacerbate chronic mycobacterium tuberculosis infection in mice
Arthritis Rheum
Utilization of host resistance models (HRMs) in the prediction of human safety of abatacept (ABA): a translational approach
Arthritis Rheum
Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis
Clin Exp Rheumatol
Hospitalized infections in the abatacept RA clinical development program: an updated epidemiological assessment with >10,000 person-years of exposure
Arthritis Rheum
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007
Ann Rheum Dis
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlledtrial
Arthritis and rheumatism
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial
Annals of internal medicine
Cited by (41)
Immunosuppression, rheumatic diseases, multiple sclerosis, and Wilson's disease
2015, Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment: Third EditionSafety of biologics: Elaboration and validation of a questionnaire assessing patients' self-care safety skills: The BioSecure questionnaire. An initiative of the French Rheumatology Society Therapeutic Education section
2013, Joint Bone SpineCitation Excerpt :A steering group of 10 rheumatologists, one pharmacist and two allied health professionals specialized in biologics or in patient education elaborated an exhaustive list of skills which could be useful to deal with safety issues of biologics. The list was developed based on the data available in the literature, including follow-up and management of biologics national and international recommendations [2,6–16], and expert opinion. The literature accessed in 2009 related to tumor necrosis factor inhibitors, rituximab and abatacept; however, later in the process, data regarding tocilizumab were also searched to ensure the list of skills is applicable to all currently available biologics [17].
Screening of tuberculosis before biologics
2012, Medecine et Maladies InfectieusesCitation Excerpt :Sixty-nine cases of tuberculosis were observed (36 under infliximab, 28 under adalimumab, and 5 under etanercept) with a relative risk of 13.3 [95% CI 2.6–69.0] for infliximab, and 17.1 [95% CI 3.6–80.6] for adalimumab compared to etanercept [5]. There is no clearly identified increase of risk for tuberculosis in trials on abatacept and tocilizumab [2–4]. This does not mean there is no increase of risk since in all trials tuberculosis was screened for.